Last reviewed · How we verify
DTaP-Hep B-IPV Vaccine — Competitive Intelligence Brief
phase 3
Vaccine
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
DTaP-Hep B-IPV Vaccine (DTaP-Hep B-IPV Vaccine) — National Institute of Allergy and Infectious Diseases (NIAID). This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, and polio viruses.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DTaP-Hep B-IPV Vaccine TARGET | DTaP-Hep B-IPV Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | phase 3 | Vaccine | ||
| Comirnaty | BNT162b2 (tozinameran) | Pfizer Inc. | marketed | vaccine | SARS-CoV-2 virus | 2021-08-23 |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| IPV at 6 weeks of age | IPV at 6 weeks of age | Centers for Disease Control and Prevention | marketed | Inactivated viral vaccine | Poliovirus types 1, 2, and 3 | |
| Varicella Virus Vaccine Live | Varicella Virus Vaccine Live | Sanofi Pasteur, a Sanofi Company | marketed | Live attenuated vaccine | Varicella-zoster virus (VZV) | |
| Streptococcus pneumoniae serotype 3 | Streptococcus pneumoniae serotype 3 | University of Oxford | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae serotype 3 capsular polysaccharide | |
| PCRA (Intermittent injection) | PCRA (Intermittent injection) | Örebro University, Sweden | marketed | Cancer vaccine / Autologous cell therapy |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (Vaccine class)
- GlaxoSmithKline · 16 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
- Pfizer · 6 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
- Henogen · 3 drugs in this class
- Pfizer Inc. · 2 drugs in this class
- Sanofi · 2 drugs in this class
- Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
- BioNTech · 2 drugs in this class
- Merck Sharp & Dohme LLC · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DTaP-Hep B-IPV Vaccine CI watch — RSS
- DTaP-Hep B-IPV Vaccine CI watch — Atom
- DTaP-Hep B-IPV Vaccine CI watch — JSON
- DTaP-Hep B-IPV Vaccine alone — RSS
- Whole Vaccine class — RSS
Cite this brief
Drug Landscape (2026). DTaP-Hep B-IPV Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/dtap-hep-b-ipv-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab